Abstract: A display unit includes a plurality of light-emitting sections and an optical filter. The plurality of light-emitting sections emit color light beams having different colors. The optical filter is disposed on light emission side of the plurality of light-emitting sections, and transmits the color light beams while selectively removing a part of a wavelength band of the color light beams. The optical filter includes the first filter layer and the second filter layer. The first filter layer transmits a first band including a center wavelength out of the wavelength band of each of the color light beams, and removes a second band that is at least a part of a band other than the first band. The second filter layer reduces transmissivity of a third band that is a part of the first band of at least one color light beam out of the color light beams.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.

Abstract: A process for producing a compound represented by formula (1), wherein each of R1, R2, R3 and R4, which may be the same or different, represents a hydrogen atom or a lower alkyl group, the process includes deprotecting a protective group (R5) of a compound represented by formula (2), wherein R1, R2, R3 and R4 are as defined above, and R5 represents a protective group of a hydroxy group. The process is an industrially advantageous, simple, and efficient process for producing a key intermediate of a benzo[b][1,4]diazepine-2,4-dione compound, which is a therapeutic medicine for arrhythmia.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.

Abstract: A secondary battery includes: a cathode and an anode that are opposed to each other with a separator in between; and an electrolytic solution, wherein the cathode includes a cathode current collector and a cathode active material layer provided between the cathode current collector and the separator, the anode includes an anode current collector and an anode active material layer provided between the anode current collector and the separator, one or more of the cathode, the anode, and the separator includes a plurality of thermally-conductive particles in a region between the cathode current collector and the anode current collector, and heat conductivity of the thermally-conductive particles is larger in a second direction that intersects with a first direction, in which the cathode and the anode are opposed to each other, than in the first direction.

Abstract: A process for producing a compound represented by formula (1), wherein each of R1, R2, R3 and R4, which may be the same or different, represents a hydrogen atom or a lower alkyl group, the process includes deprotecting a protective group (R5) of a compound represented by formula (2), wherein R1, R2, R3 and R4 are as defined above, and R5 represents a protective group of a hydroxy group. The process is an industrially advantageous, simple, and efficient process for producing a key intermediate of a benzo[b][1,4]diazepine-2,4-dione compound, which is a therapeutic medicine for arrhythmia.

Abstract: A process for producing a compound represented by formula (1), wherein each of R1, R2, R3 and R4, which may be the same or different, represents a hydrogen atom or a lower alkyl group, the process includes deprotecting a protective group (R5) of a compound represented by formula (2), wherein R1, R2, R3 and R4 are as defined above, and R5 represents a protective group of a hydroxy group. The process is an industrially advantageous, simple, and efficient process for producing a key intermediate of a benzo[b][1,4]diazepine-2,4-dione compound, which is a therapeutic medicine for arrhythmia.

Abstract: There is provided a battery including a positive electrode, a negative electrode, and an electrolyte. The positive electrode includes a positive electrode active material layer, on at least one surface of a positive electrode current collector, including a binder and a positive electrode active material of a deoxidized lithium transition metal composite oxide. The positive electrode active material layer shows first and second peaks of oxygen amounts generated from a type of the positive electrode active material in the positive electrode active material layer when the positive electrode active material layer is heated in a charge state of higher than or equal to 4.2 V and lower than or equal to 4.5 V in a lithium antipode potential, the second peak appearing in a temperature region higher than a temperature region of the first peak. At least the second peak appears in a temperature region higher than 220° C.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.

Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period.

Abstract: The present invention relates to a process for producing an MEK-modified resorcinol-formalin resin, in which recovery and reuse of the specific raw materials (water, calcium chloride, and methyl ethyl ketone (MEK)), and methanol contained in formalin, are carried out in parallel. Using this closed-system recycle production method, a resorcinol-formalin resin aqueous solution can be obtained, wherein the resin aqueous solution has a reaction product concentration of from 30 to 80%, moderate flowability with a pH of 6 to 10, a calcium chloride concentration of 100 ppm or less, a peak area corresponding to a resorcinol monomer of from 3 to 9% to the entire peak area obtained by gel permeation chromatography analysis, and a peak area corresponding to resorcinol pentanuclear or higher nuclear bodies of from 30 to 55% to the entire peak.

Abstract: This invention provides a process for preparing benzazepine compounds of the formula (1): wherein X1 is a halogen atom, R1 and R2 are a lower alkyl group, or salts thereof as well as intermediate benzoic acid compounds in high yield and high purity on industrial scale, which are useful as an intermediate for preparing a pharmaceutically active 2,3,4,5-tetrahydro-1H-1-benzazepine compound having vasopressin antagonistic activity.